These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 33368414

  • 1. Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a.
    Imamura R, Kitagawa S, Kubo T, Irie A, Kariu T, Yoneda M, Kamba T, Imamura T.
    Prostate; 2021 Feb; 81(3):147-156. PubMed ID: 33368414
    [Abstract] [Full Text] [Related]

  • 2. Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88).
    Nitta H, Wada Y, Kawano Y, Murakami Y, Irie A, Taniguchi K, Kikuchi K, Yamada G, Suzuki K, Honda J, Wilson-Morifuji M, Araki N, Eto M, Baba H, Imamura T.
    Clin Cancer Res; 2013 Apr 15; 19(8):2004-13. PubMed ID: 23287562
    [Abstract] [Full Text] [Related]

  • 3. C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways.
    Maeda Y, Kawano Y, Wada Y, Yatsuda J, Motoshima T, Murakami Y, Kikuchi K, Imamura T, Eto M.
    Oncol Rep; 2015 Apr 15; 33(4):1844-50. PubMed ID: 25682807
    [Abstract] [Full Text] [Related]

  • 4. Influence of the C5a-C5a receptor system on breast cancer progression and patient prognosis.
    Imamura T, Yamamoto-Ibusuki M, Sueta A, Kubo T, Irie A, Kikuchi K, Kariu T, Iwase H.
    Breast Cancer; 2016 Nov 15; 23(6):876-885. PubMed ID: 26494574
    [Abstract] [Full Text] [Related]

  • 5. C5a receptor (CD88) promotes motility and invasiveness of gastric cancer by activating RhoA.
    Kaida T, Nitta H, Kitano Y, Yamamura K, Arima K, Izumi D, Higashi T, Kurashige J, Imai K, Hayashi H, Iwatsuki M, Ishimoto T, Hashimoto D, Yamashita Y, Chikamoto A, Imanura T, Ishiko T, Beppu T, Baba H.
    Oncotarget; 2016 Dec 20; 7(51):84798-84809. PubMed ID: 27756879
    [Abstract] [Full Text] [Related]

  • 6. C5a receptor enhances hepatocellular carcinoma cell invasiveness via activating ERK1/2-mediated epithelial-mesenchymal transition.
    Hu WH, Hu Z, Shen X, Dong LY, Zhou WZ, Yu XX.
    Exp Mol Pathol; 2016 Feb 20; 100(1):101-8. PubMed ID: 26475622
    [Abstract] [Full Text] [Related]

  • 7. Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer.
    Wang F, Wu L, Yin L, Shi H, Gu Y, Xing N.
    Clin Transl Med; 2022 Jun 20; 12(6):e901. PubMed ID: 35696531
    [Abstract] [Full Text] [Related]

  • 8. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Xu L, Shen M, Chen X, Zhu R, Yang DR, Tsai Y, Keng PC, Chen Y, Lee SO.
    Prostate; 2018 Apr 20; 78(5):353-364. PubMed ID: 29330929
    [Abstract] [Full Text] [Related]

  • 9. A Crosstalk Between Castration-Resistant Prostate Cancer Cells, M2 Macrophages, and NK Cells: Role of the ATM-PI3K/AKT-PD-L1 Pathway.
    Jin H, Zhu J, Xuan R, Zhou Y, Xue B, Yang D, Gao J, Zang Y, Xu L.
    Immunol Invest; 2023 Nov 20; 52(8):941-965. PubMed ID: 37732622
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Enhancement of cancer invasion and growth via the C5a-C5a receptor system: Implications for cancer promotion by autoimmune diseases and association with cervical cancer invasion.
    Yoneda M, Imamura R, Nitta H, Taniguchi K, Saito F, Kikuchi K, Ogi H, Tanaka T, Katabuchi H, Nakayama H, Imamura T.
    Oncol Lett; 2019 Jan 20; 17(1):913-920. PubMed ID: 30655847
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Receptors for the anaphylatoxin C5a (CD88) on human mesangial cells.
    Wilmer WA, Kaumaya PT, Ember JA, Cosio FG.
    J Immunol; 1998 Jun 01; 160(11):5646-52. PubMed ID: 9605171
    [Abstract] [Full Text] [Related]

  • 15. C5aR deficiency attenuates the breast cancer development via the p38/p21 axis.
    Chen J, Sun ZH, Chen LY, Xu F, Zhao YP, Li GQ, Tang M, Li Y, Zheng QY, Wang SF, Yang XH, Wu YZ, Xu GL.
    Aging (Albany NY); 2020 Jul 15; 12(14):14285-14299. PubMed ID: 32669478
    [Abstract] [Full Text] [Related]

  • 16. Mesenchymal stem cells alleviate acute kidney injury by down-regulating C5a/C5aR pathway activation.
    Tang M, Zhang K, Li Y, He QH, Li GQ, Zheng QY, Zhang KQ.
    Int Urol Nephrol; 2018 Aug 15; 50(8):1545-1553. PubMed ID: 29594894
    [Abstract] [Full Text] [Related]

  • 17. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
    Kang M, Lee KH, Lee HS, Park YH, Jeong CW, Ku JH, Kim HH, Kwak C.
    Prostate; 2016 Feb 15; 76(3):273-85. PubMed ID: 26499308
    [Abstract] [Full Text] [Related]

  • 18. Function, structure and therapeutic potential of complement C5a receptors.
    Monk PN, Scola AM, Madala P, Fairlie DP.
    Br J Pharmacol; 2007 Oct 15; 152(4):429-48. PubMed ID: 17603557
    [Abstract] [Full Text] [Related]

  • 19. γδT-cell function in sepsis is modulated by C5a receptor signalling.
    Han G, Geng S, Li Y, Chen G, Wang R, Li X, Ma Y, Shen B, Li Y.
    Immunology; 2011 Jul 15; 133(3):340-9. PubMed ID: 21501163
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.